|Bid||1.2300 x 1000|
|Ask||1.4000 x 1100|
|Day's range||0.0523 - 0.0523|
|52-week range||0.0400 - 4.7430|
|Beta (5Y monthly)||0.04|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
NEW YORK, January 12, 2022--PAVmed and Lucid Diagnostics welcome new full-time investor relations team.
NEW YORK, January 06, 2022--Lucid Diagnostics to participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference.
Specalty medical-device maker PAVmed (NASDAQ: PAVM) didn't make for a great stock on Wednesday. PAVmed filed a shelf-registration statement with the Securities and Exchange Commission earlier in the day. In PAVmed's case, it's aiming to float $275 million worth of one or more of: common stock, preferred stock, warrants, debt securities, and units (i.e., a combination of at least two of the preceding types of securities).